Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$3.2 million.

  • Cytosorbents' Net Income towards Common Stockholders fell 1452.31% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.3 million, marking a year-over-year increase of 4667.13%. This contributed to the annual value of -$20.7 million for FY2024, which is 2915.81% up from last year.
  • As of Q3 2025, Cytosorbents' Net Income towards Common Stockholders stood at -$3.2 million, which was down 1452.31% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Net Income towards Common Stockholders peaked at $1.9 million during Q2 2025, and registered a low of -$12.2 million during Q3 2022.
  • Over the past 5 years, Cytosorbents' median Net Income towards Common Stockholders value was -$6.2 million (recorded in 2023), while the average stood at -$5.8 million.
  • As far as peak fluctuations go, Cytosorbents' Net Income towards Common Stockholders crashed by 127327.47% in 2021, and later surged by 14534.23% in 2025.
  • Cytosorbents' Net Income towards Common Stockholders (Quarter) stood at -$9.3 million in 2021, then skyrocketed by 91.77% to -$766128.0 in 2022, then plummeted by 661.61% to -$5.8 million in 2023, then fell by 29.68% to -$7.6 million in 2024, then skyrocketed by 58.11% to -$3.2 million in 2025.
  • Its last three reported values are -$3.2 million in Q3 2025, $1.9 million for Q2 2025, and -$1.5 million during Q1 2025.